Astellas’ Mike Luther sees 2023 as a year of growing assets and creating partnerships. The global head of search and evaluation business development told In Vivo about the company's focus on gene and cell therapy and what he thinks makes for a successful business deal.
Sentiments around the 2023 biopharma dealmaking environment may be mixed, but Mike Luther, the global head of search and evaluation business development at Astellas Pharma, Inc., hopes the coming year will be defined by handshakes and signatures for the Japanese pharma.
“This year, as I see it, it will be 'execute, execute, execute,' to pull in the deals and the investments...
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
